• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

儿童和成人肾移植受者中霉酚酸(MPA)的药代动力学及MPA游离分数的决定因素。德国儿童肾移植受者霉酚酸酯治疗研究组。

Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients.

作者信息

Weber L T, Shipkova M, Lamersdorf T, Niedmann P D, Wiesel M, Mandelbaum A, Zimmerhackl L B, Schütz E, Mehls O, Oellerich M, Armstrong V W, Tönshoff B

机构信息

Division of Pediatric Nephrology, University Children's Hospital Heidelberg, Germany.

出版信息

J Am Soc Nephrol. 1998 Aug;9(8):1511-20. doi: 10.1681/ASN.V981511.

DOI:10.1681/ASN.V981511
PMID:9697675
Abstract

Dosage guidelines for mycophenolate mofetil (MMF), an ester prodrug of the immunosuppressant mycophenolic acid (MPA), are still preliminary in children. This study compares the pharmacokinetics of MPA and its major metabolite MPA glucuronide (MPAG) in pediatric renal transplant recipients receiving 600 mg MMF/m2 body surface area twice a day to those of adults on the currently recommended oral dose of 1 g of MMF twice a day. Concentration-time profiles of 18 children (age, 10.7+/-0.72 yr; range, 5.9 to 15.3 yr) and 10 adults were investigated 1 and 3 wk after transplantation. Plasma concentrations of MPA and MPAG were measured by reverse-phase HPLC. Because MPA is extensively bound to serum albumin and only the free fraction is presumed to be pharmacologically active, the MPA free fraction was also analyzed by HPLC after separation through ultrafiltration. The areas under the concentration-time curves (AUC0-12) of total and free MPA throughout the 12-h dosing interval in children were, in general, comparable to the corresponding data in adult patients. The mean AUC0-12 of MPA and free MPA did not change significantly over the first 3 wk after transplantation, but there was substantial intra- and interindividual variation. MPAG-AUC0-12 values in children with primary renal transplant dysfunction were threefold higher than in those with functioning transplants. Renal impairment had no consistent effect on total MPA-AUC0-12 values, but the MPA free fraction in children (median, 1.65%; range, 0.40 to 13.8%) was significantly (r2=0.46) modulated by renal transplant function and serum albumin levels. In conclusion, concentration-time profiles of pediatric renal transplant recipients administered 600 mg MMF/m2 body surface area twice a day are comparable to those in adults on 1 g MMF twice a day in the first 3 wk after transplantation. Renal impairment and decreased serum albumin levels led to an increase in the free fraction of MPA and the free MPA-AUC0-12 values. Because the pharmacologic activity of MPA is a function of unbound drug concentration, these findings might be relevant for the pharmacodynamic effects of MPA.

摘要

霉酚酸酯(MMF)是免疫抑制剂霉酚酸(MPA)的酯前体药物,其在儿童中的用药指南仍处于初步阶段。本研究比较了接受每日两次600mg MMF/m²体表面积的儿科肾移植受者中MPA及其主要代谢产物MPA葡糖醛酸酯(MPAG)的药代动力学与接受当前推荐口服剂量每日两次1g MMF的成人的药代动力学。在移植后1周和3周对18名儿童(年龄,10.7±0.72岁;范围,5.9至1

相似文献

1
Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients.儿童和成人肾移植受者中霉酚酸(MPA)的药代动力学及MPA游离分数的决定因素。德国儿童肾移植受者霉酚酸酯治疗研究组。
J Am Soc Nephrol. 1998 Aug;9(8):1511-20. doi: 10.1681/ASN.V981511.
2
Area under the plasma concentration-time curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: a longitudinal study in pediatric patients. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients.肾移植稳定期血浆中总麦考酚酸而非游离麦考酚酸的浓度-时间曲线下面积增加:一项针对儿科患者的纵向研究。德国儿科肾移植受者霉酚酸酯治疗研究组。
Ther Drug Monit. 1999 Oct;21(5):498-506. doi: 10.1097/00007691-199910000-00002.
3
Clinical pharmacokinetics of mycophenolate mofetil.霉酚酸酯的临床药代动力学。
Clin Pharmacokinet. 1998 Jun;34(6):429-55. doi: 10.2165/00003088-199834060-00002.
4
Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.在接受环孢素或西罗莫司联合治疗的稳定肾移植患者中,霉酚酸曲线下面积预测的有限采样模型和贝叶斯估计
Clin Pharmacokinet. 2009;48(11):745-58. doi: 10.2165/11318060-000000000-00000.
5
Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function.肾移植术后移植肾功能延迟恢复患者霉酚酸的药代动力学
J Clin Pharmacol. 1998 Mar;38(3):268-75. doi: 10.1002/j.1552-4604.1998.tb04424.x.
6
Trough levels of mycophenolic acid and its glucuronidated metabolite in renal transplant recipients.肾移植受者中霉酚酸及其葡萄糖醛酸化代谢物的谷浓度
Int J Clin Pharmacol Ther. 2005 Aug;43(8):379-88. doi: 10.5414/cpp43379.
7
Renal graft function and low-dose cyclosporine affect mycophenolic acid pharmacokinetics in kidney transplantation.肾移植中移植物功能和低剂量环孢素影响麦考酚酸的药代动力学。
Transplantation. 2011 Sep 15;92(5):550-6. doi: 10.1097/TP.0b013e318225dbd0.
8
Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients.儿科肾移植受者中麦考酚酸具有药理活性的酰基葡萄糖醛酸代谢物的药代动力学及蛋白加合物形成
Ther Drug Monit. 2002 Jun;24(3):390-9. doi: 10.1097/00007691-200206000-00011.
9
Pharmacokinetics and tolerance of mycophenolate mofetil in renal transplant children.霉酚酸酯在儿童肾移植受者中的药代动力学及耐受性
Pediatr Nephrol. 2000 Feb;14(2):95-9. doi: 10.1007/s004670050020.
10
Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients.麦考酚酸及其葡萄糖醛酸代谢物的蛋白结合在肾移植受者中的药代动力学作用。
J Pharmacokinet Pharmacodyn. 2009 Dec;36(6):541-64. doi: 10.1007/s10928-009-9136-6. Epub 2009 Nov 11.

引用本文的文献

1
Model-informed dose optimization of mycophenolic acid in pediatric kidney transplant patients.基于模型的儿童肾移植患者麦考酚酸剂量优化。
Eur J Clin Pharmacol. 2024 Nov;80(11):1761-1771. doi: 10.1007/s00228-024-03743-0. Epub 2024 Aug 17.
2
Significant Effects of Renal Function on Mycophenolic Acid Total Clearance in Pediatric Kidney Transplant Recipients with Population Pharmacokinetic Modeling.基于群体药代动力学模型的肾功能对儿科肾移植受者麦考酚酸总清除率的显著影响。
Clin Pharmacokinet. 2023 Sep;62(9):1289-1303. doi: 10.1007/s40262-023-01280-0. Epub 2023 Jul 26.
3
Treatment optimization of maintenance immunosuppressive agents in pediatric renal transplant recipients.
儿科肾移植受者维持性免疫抑制药物的治疗优化。
Expert Opin Drug Metab Toxicol. 2021 Jul;17(7):747-765. doi: 10.1080/17425255.2021.1943356. Epub 2021 Jun 29.
4
Mycophenolic Acid Trough Concentration and Dose Are Associated with Hematologic Abnormalities but Not Rejection in Kidney Transplant Recipients.霉酚酸谷浓度和剂量与肾移植受者的血液学异常有关,但与排斥无关。
J Korean Med Sci. 2020 Jun 22;35(24):e185. doi: 10.3346/jkms.2020.35.e185.
5
Calcineurin Inhibitors and Neutropenia: Is Cyclosporine Superior to Tacrolimus?钙调神经磷酸酶抑制剂与中性粒细胞减少症:环孢素比他克莫司更具优势吗?
Am J Case Rep. 2019 Sep 24;20:1407-1410. doi: 10.12659/AJCR.917282.
6
Early pharmacokinetics of low dosage mycophenolate exposure in Thai kidney transplant recipients.泰国肾移植受者中低剂量霉酚酸暴露的早期药代动力学。
Int J Clin Pharm. 2019 Aug;41(4):1047-1055. doi: 10.1007/s11096-019-00848-w. Epub 2019 May 25.
7
Prediction of Free from Total Mycophenolic Acid Concentrations in Stable Renal Transplant Patients: A Population-Based Approach.稳定期肾移植患者麦考酚酸游离浓度预测:基于人群的方法。
Clin Pharmacokinet. 2018 Jul;57(7):877-893. doi: 10.1007/s40262-017-0603-8.
8
Pharmacokinetics of mycophenolic acid in children with clinically stable idiopathic nephrotic syndrome receiving cyclosporine.接受环孢素治疗的临床稳定的特发性肾病综合征患儿霉酚酸的药代动力学
Clin Exp Nephrol. 2017 Feb;21(1):152-158. doi: 10.1007/s10157-016-1267-7. Epub 2016 Apr 22.
9
The compelling case for therapeutic drug monitoring of mycophenolate mofetil therapy.对霉酚酸酯治疗进行治疗药物监测的有力理由。
Pediatr Nephrol. 2017 Jan;32(1):21-29. doi: 10.1007/s00467-016-3352-2. Epub 2016 Feb 26.
10
Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II.异基因造血细胞移植中免疫抑制剂的药代动力学、药效学和药物基因组学:第二部分。
Clin Pharmacokinet. 2016 May;55(5):551-93. doi: 10.1007/s40262-015-0340-9.